“Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma” (2023) Molecular Medicine Communications, 3(02), pp. 89–92. doi:10.55627/mmc.003.02.0461.